Ebos Group Ltd (ASX: EBO) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Ebos Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $4.39 billion
P/E Ratio 21.94
Dividend Yield 4.29%
Shares Outstanding 203.26 million
Earnings per share 1.174
Dividend per share 0.98
Year To Date Return -6.30%
Earnings Yield 4.56%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Ebos Group Ltd (ASX: EBO)
    Latest News

    A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
    Healthcare Shares

    Ahead of its earnings results, Macquarie reckons this healthcare company is severely undervalued

    A surprise on the upside is a definite possibility.

    Read more »

    Two men laughing while bouncing on bouncy balls
    Share Market News

    Can these 2 ASX 200 shares rebound after reaching record lows?

    Brokers see 30-50% upside for the battered stocks.

    Read more »

    A young woman with a ponytail stands at the crossroads, trying to choose between one way or the other.
    Value Investing

    2 undervalued ASX 200 shares to target

    These could be rebound candidates in 2026.

    Read more »

    A cute little boy, short in height, wearing glasses, old-fashioned bow tie and cardigan stands against a wall near a tape measure with his hand at the top of his head as though to measure his height.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a fairly awful end to the trading week.

    Read more »

    a woman drawing image on wall of big fish about to eat a small fish
    Mergers & Acquisitions

    Macquarie names 16 potential ASX takeover targets

    The broker thinks these shares could be taken over in the near term.

    Read more »

    Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    The S&P/ASX 200 Index (ASX: XJO) finished up the trading week on a positive note this Friday, following on from…

    Read more »

    A woman sits in her home with chin resting on her hand and looking at her laptop computer with some reflection with an assortment of books and documents on her table.
    Cheap Shares

    This $5 billion ASX 300 share just hit a 52-week low, is it a buy?

    Is this business a very healthy opportunity?

    Read more »

    A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
    Share Market News

    9 ASX shares including Droneshield, GQG, and Tuas about to enter ASX 200

    S&P Dow Jones Indices has just announced details of the September quarter rebalance.

    Read more »

    A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
    Broker Notes

    These top ASX shares could rise 20%+

    Macquarie is tipping these shares to deliver market-beating gains.

    Read more »

    A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
    Earnings Results

    This ASX 200 healthcare stock crashed 14% to 4-year low. Here's what happened

    Spooked investors sold off their shares.

    Read more »

    Teen standing in a city street smiling and throwing sparkling gold glitter into the air.
    52-Week Highs

    11 ASX 200 stocks streaking to multi-year highs today

    The benchmark ASX 200 is in the green and these 11 stocks are setting new price records.

    Read more »

    Stethoscope with a piggy bank and hundred dollar notes.
    Healthcare Shares

    Which ASX 200 healthcare share will pay the best dividend yield in 2025?

    Earnings season is underway and dividend announcements are on investors' minds.

    Read more »

    Frequently Asked Questions

    Yes, EBOS Group has historically paid two partially franked shareholder dividends a year.

    EBOS Group generally pays its shareholder dividends in March and September. 

    Yes, EBOS has a dividend reinvestment plan to allow shareholders to reinvest all or part of their dividends.

    EBOS Group Ltd listed on the ASX on 6 September 2013.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    04 Sep 2025 $0.6150 0.00% Final 24 Sep 2025
    27 Feb 2025 $0.0251 0.00% Supplemental 21 Mar 2025
    29 Aug 2024 $0.5043 0.00% Final 18 Sep 2024
    29 Feb 2024 $0.1510 0.00% Supplemental 22 Mar 2024
    07 Sep 2023 $0.0251 0.00% Supplemental 29 Sep 2023
    07 Sep 2023 $0.4705 0.00% Final 29 Sep 2023
    02 Mar 2023 $0.0234 0.00% Supplemental 17 Mar 2023
    02 Mar 2023 $0.4259 0.00% Interim 17 Mar 2023
    08 Sep 2022 $0.0216 0.00% Supplemental 30 Sep 2022
    08 Sep 2022 $0.3800 0.00% Final 30 Sep 2022
    03 Mar 2022 $0.0207 0.00% Supplemental 18 Mar 2022
    03 Mar 2022 $0.3917 0.00% Interim 18 Mar 2022
    09 Sep 2021 $0.0203 0.00% Supplemental 24 Sep 2021
    09 Sep 2021 $0.3953 0.00% Final 24 Sep 2021
    04 Mar 2021 $0.0188 0.00% Supplemental 18 Mar 2021
    04 Mar 2021 $0.3506 0.00% Interim 18 Mar 2021
    24 Sep 2020 $0.0176 0.00% Supplemental 09 Oct 2020
    24 Sep 2020 $0.3289 0.00% Final 09 Oct 2020
    12 Mar 2020 $0.0165 0.00% Supplemental 03 Apr 2020
    12 Mar 2020 $0.3232 0.00% Interim 03 Apr 2020
    26 Sep 2019 $0.0163 0.00% Supplemental 11 Oct 2019
    26 Sep 2019 $0.3076 0.00% Final 11 Oct 2019
    14 Mar 2019 $0.0152 0.00% Supplemental 05 Apr 2019
    14 Mar 2019 $0.2920 0.00% Interim 05 Apr 2019
    27 Sep 2018 $0.2871 0.00% Final 12 Oct 2018
    15 Mar 2018 $0.0146 0.00% Supplemental 06 Apr 2018
    15 Mar 2018 $0.2766 0.00% Interim 06 Apr 2018
    28 Sep 2017 $0.0146 0.00% Supplemental 13 Oct 2017
    28 Sep 2017 $0.2664 0.00% Final 13 Oct 2017
    16 Mar 2017 $0.2453 0.00% Interim 07 Apr 2017
    29 Sep 2016 $0.2697 0.00% Final 14 Oct 2016
    10 Mar 2016 $0.2075 0.00% Interim 01 Apr 2016
    30 Sep 2015 $0.2024 0.00% Final 16 Oct 2015
    11 Mar 2015 $0.1884 0.00% Interim 02 Apr 2015
    01 Oct 2014 $0.1650 0.00% Final 17 Oct 2014
    12 Mar 2014 $0.1776 0.00% Interim 04 Apr 2014
    06 Apr 2011 $0.1350 0.00% Interim 21 Apr 2011
    08 Sep 2010 $0.1750 0.00% Final 08 Oct 2010
    15 Mar 2010 $0.1350 0.00% Interim 13 Apr 2010
    07 Sep 2009 $0.1450 0.00% Final 02 Oct 2009
    23 Mar 2009 $0.1050 0.00% Interim 21 Apr 2009
    15 Sep 2008 $0.0238 0.00% Supplemental 10 Oct 2008
    15 Sep 2008 $0.1350 0.00% Final 10 Oct 2008
    14 Apr 2008 $0.0168 0.00% Supplemental 09 May 2008
    14 Apr 2008 $0.0950 0.00% Interim 09 May 2008
    23 Oct 2007 $0.0229 0.00% Supplemental 26 Oct 2007
    23 Oct 2007 $0.1300 0.00% Final 26 Oct 2007
    16 Apr 2007 $0.0168 0.00% Supplemental 20 Apr 2007
    16 Apr 2007 $0.0950 0.00% Interim 20 Apr 2007
    24 Oct 2006 $0.0229 0.00% Supplemental 27 Oct 2006
    24 Oct 2006 $0.1300 0.00% Final 27 Oct 2006
    03 Apr 2006 $0.0168 0.00% Supplemental 07 Apr 2006
    03 Apr 2006 $0.0950 0.00% Interim 07 Apr 2006
    03 Oct 2005 $0.0221 0.00% Supplemental 07 Oct 2005
    03 Oct 2005 $0.1250 0.00% Final 07 Oct 2005
    14 Mar 2005 $0.0159 0.00% Supplemental 18 Mar 2005
    14 Mar 2005 $0.0900 0.00% Interim 18 Mar 2005

    EBO ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Ebos Group Ltd

    EBOS Group Ltd (ASX: EBO) is the largest pharmaceutical wholesaler and distributor across Australia, New Zealand, and Southeast Asia. The company provides pharmaceutical and wellness products to community pharmacies, public and private hospitals, day surgeries, general practices, aged care facilities, and specialist clinics.

    EBOS Group also operates an animal health product wholesale, manufacturing, and retail business, as well as providing third-party logistics services.

    The vast majority of the company's revenue derives from its services to community pharmacies and institutional healthcare providers, which accounts for about 80% of revenue. Its Australian operations similarly contribute around 80% of its total revenue.

     

    EBO Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    06 Feb 2026 $21.41 $-0.74 -3.34% 86,685 $21.79 $22.08 $21.35
    05 Feb 2026 $22.15 $0.33 1.51% 83,727 $21.95 $22.38 $21.82
    04 Feb 2026 $21.82 $-0.03 -0.14% 114,831 $21.81 $22.09 $21.61
    03 Feb 2026 $21.85 $-0.56 -2.50% 130,944 $23.08 $23.08 $21.74
    02 Feb 2026 $22.41 $0.31 1.40% 60,096 $21.85 $22.43 $21.85
    30 Jan 2026 $22.10 $0.40 1.84% 89,688 $22.55 $22.55 $21.87
    29 Jan 2026 $21.70 $-0.44 -1.99% 238,141 $22.00 $22.25 $21.63
    28 Jan 2026 $22.14 $-0.77 -3.36% 122,177 $22.89 $23.05 $22.03
    27 Jan 2026 $22.91 $0.07 0.31% 175,127 $23.00 $23.26 $22.72
    23 Jan 2026 $22.84 $0.13 0.57% 167,231 $22.75 $23.09 $22.75
    22 Jan 2026 $22.71 $0.17 0.75% 233,568 $22.42 $22.91 $22.42
    21 Jan 2026 $22.54 $-0.05 -0.22% 61,686 $22.87 $22.87 $22.49
    20 Jan 2026 $22.59 $-0.16 -0.70% 95,308 $22.40 $22.74 $22.36
    19 Jan 2026 $22.75 $0.05 0.22% 102,175 $22.70 $22.75 $22.30
    16 Jan 2026 $22.70 $0.13 0.58% 107,906 $22.50 $22.88 $22.45
    15 Jan 2026 $22.57 $0.03 0.13% 83,844 $22.51 $22.70 $22.28
    14 Jan 2026 $22.54 $-0.14 -0.62% 375,981 $23.00 $23.00 $22.54
    13 Jan 2026 $22.68 $-0.82 -3.49% 160,619 $23.50 $23.63 $22.68
    12 Jan 2026 $23.50 $0.06 0.26% 62,786 $23.44 $23.74 $23.42
    09 Jan 2026 $23.44 $-0.04 -0.17% 71,826 $23.60 $23.73 $23.39
    08 Jan 2026 $23.48 $-0.15 -0.63% 51,684 $23.43 $23.85 $23.43

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    05 Dec 2025 Coline McConville Buy 1,000 $24,347
    On-market trade.
    27 Nov 2025 Julie Tay Buy 1,000 $28,000
    On-market trade. NZ$
    10 Nov 2025 Matthew Muscio Buy 3,800 $108,563
    On-market trade. NZ$
    30 Oct 2025 Tracey Batten Buy 2,728 $67,531
    On-market trade.
    21 Oct 2025 Mark Bloom Buy 1,500 $37,647
    On-market trade.
    07 Oct 2025 Julie Tay Buy 2,000 $52,000
    On-market trade.
    24 Sep 2025 Stuart McLauchlan Issued 56 $1,623
    Dividend Reinvestment Plan (DRP). NZ$
    23 Sep 2025 Elizabeth(Liz) Coutts Buy 3,000 $87,903
    On-market trade. NZ$
    22 Sep 2025 Stuart McLauchlan Buy 1,000 $29,200
    On-market trade. NZ$
    04 Sep 2025 Matthew Muscio Expiry 15,828 $443,975
    As advised by the company. Lapse of performance rights
    17,859 performance rights
    30 May 2025 Mark Bloom Buy 2,000 $68,800
    On-market trade.
    13 May 2025 Elizabeth(Liz) Coutts Issued 1,364 $49,990
    Issue of securities. NZ$, retail offer
    13 May 2025 Stuart McLauchlan Issued 95 $3,481
    Issue of securities. NZ$, retail offer
    13 May 2025 Tracey Batten Issued 272 $9,968
    Issue of securities. NZ$ retail offer
    21 Mar 2025 Stuart McLauchlan Issued 39 $1,442
    Dividend Reinvestment Plan (DRP). NZ$

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Elizabeth(Liz) Mary Coutts Non-Executive DirectorNon-Executive Chairman Nov 2013
    Ms Coutts is a former Chair of Skellerup Holdings Limited, Ports of Auckland Limited, Meritec Group, Industrial Research, Life Pharmacy Limited, former director of Air New Zealand Limited, the Health Funding Authority, Sanford Limited, the Yellow Group of Companies and Tennis Auckland Region Incorporated, former Deputy Chairman of Public Trust, former board member of Sport NZ, former member of the Pharmaceutical Management Agency (Pharmac) and Marsh New Zealand Advisory Board, former Commissioner for both the Commerce and Earthquake Commissions, former external monetary policy adviser to the Governor of the Reserve Bank of New Zealand, a former president of the Institute of Directors Inc and former Chief Executive of the Caxton Group of Companies. She is a member of the Risk Committee.
    Mr Mark Alan Bloom Non-Executive Director Sep 2022
    Mr Bloom is a former director of Pacific Smiles Group Limited and Abacus Property Group. Mark has over 35 years of experience as a finance executive. Prior to this, he was Deputy Group CFO of Westfield Group for 11 years. Mark has also held several senior finance roles, including being CFO and executive director for insurance and financial services companies Liberty Life, South Africa and Manulife Financial, Canada. Mark is a member of the Audit and Risk Committee.
    Mr Stuart McLauchlan Non-Executive Director Jul 2019
    Mr McLauchlan is a partner of GS McLauchlan & Co. He is currently chairman of Scott Technology Ltd, ADInstruments Ltd, Cargill Hotel 2022 Ltd, Otago Community Hospice and Woods Solutions. He is the director of Argosy Properties Ltd and Scenic Hotels Group, as as several private companies. He is also a governor of the New Zealand Sports Hall of Fame. He was formerly a chairman of Pharmac and UDC Finance, member of the Marsh New Zealand Advisory Board, and director of Ngai Tahu Tourism Ltd. He is Chairman of the Risk Committee.
    Mr Matthew Peter Muscio Non-Executive Director Jan 2025
    Mr Muscio's career spans more than 25 years in the medical device industry with the last 15 years in medical technology distribution under both public and private ownership models. Matt has been a board member for the Medical Technology Association of Australia from 2017 to 2023 and currently serves as a non-executive board member for Tetrous Inc, a regenerative medicine company.
    Dr Tracey Leigh Batten Non-Executive Director Jul 2021
    Dr Batten is currently a non-executive director of Medibank Private Limited and Nanosonics Limited. She was previously Chair of the Accident Compensation Corporation, a non-executive director of National Institute of Water and Atmospheric Research, Abano Healthcare Group Limited and various other healthcare related research institutes, charities and industry and government bodies. During her executive career she was Group CEO of Imperial College Healthcare NHS Trust in the United Kingdom, Group CEO of St Vincent's Health Australia, CEO of Eastern Health and CEO of Dental Health Services Victoria. Mark is a member of the Risk Committee.
    Ms Julie Tay Non-Executive Director May 2023
    Ms Tay is currently a director of Sonova, a global hearing care solutions company, headquartered in Switzerland and listed on the Swiss stock exchange. She has over 30 years of experience in international executive and non-executive roles across consumer healthcare, medical devices and digital healthcare. Julie was most recently Senior Vice President and Managing Director, Asia Pacific and member of the global Executive Management Committee for Align Technology. Prior to this, she was regional head of Bayer Healthcare (Diabetes Care) in Asia Pacific and previously held senior executive roles in Asia at Johnson Diversey and Johnson & Johnson.
    Ms Coline McConville Non-Executive Director Feb 2025
    Ms McConville has 20 years of governance experience advising a range of organizations operating in different countries and industries. Her expertise includes advising across acquisitive portfolio companies, complex distribution organizations, capital intensive businesses, consumer driven vertically integrated and global service companies. During her executive career, Ms McConville was Chief Executive Officer and Chief Operating Officer for Clear Channel Communications (now iHeartMedia Inc.) and a management consultant with McKinsey and Co and LEK Consulting. She is currently a director of 3i Group and a member of the Supervisory Board of Germany-based Tui AG. Her previous directorships include Kings Cross Central General Partnership, TUI Travel, UTV Media, Travis Perkins, Fevertree Drinks, Inchcape, Wembley National Stadium, Shed Media, Halifax and HBOS.
    Grant Viney CEO Animal Care
    -
    Kristine James CEO Medical Technology
    -
    Brett Barons CEO Symbion & Healthcare Distribution
    -
    Alistair Gray Chief Financial Officer
    -
    Mithran Naiker Chief Information Officer
    -
    Martin Krauskopf Chief Strategy and Corporate Development Officer
    -
    David Lewis EGM
    -
    Simon Bunde EGM Strategic Operations ESG and Innovation
    -
    Jacinta McCarthy Executive General Manager Human Resources
    -
    Janelle Cain General Counsel
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    JP Morgan Nominees Australia Limited 25,085,843 12.34%
    HSBC Nominees (New Zealand) Limited NZCSD 14,677,082 7.22%
    HSBC Custody Nominees (Australia) Limited 13,682,865 6.73%
    BNP Paribas Nominees (NZ) Limited NZCSD 13,500,892 6.64%
    Custodial Services Limited 12,678,532 6.24%
    Sybos Holdings PTE Limited 9,957,825 4.90%
    Forsyth Barr Custodians Limited 8,616,830 4.24%
    HSBC Nominees (New Zealand) Limited A/C State Street NZCSD 8,506,099 4.19%
    Tea Custodians Limited Client Property Trust Account NZCSD 8,317,469 4.09%
    JPMorgan Chase Bank NA NZ Branch-Segregated Clients Acct NZCSD 7,772,261 3.82%
    Citibank Nominees (New Zealand) Limited NZCSD 7,202,785 3.54%
    Accident Compensation Corporation NZCSD 6,391,154 3.15%
    HSBC Nominees A/C NZ Superannuation Fund Nominees Limited NZCSD 5,480,889 2.70%
    FNZ Custodians Limited 4,197,368 2.07%
    JBWere (NZ) Nominees Limited 2,804,413 1.38%
    ANZ Wholesale Australasian Share Fund NZCSD 2,655,236 1.31%
    Citicorp Nominees Pty Limited 2,612,454 1.29%
    New Zealand Depository Nominee Limited 2,499,353 1.23%
    Generate Kiwisaver Public Trust Nominees Limited <NZCSD> 2,020,090 0.99%
    Simplicity Nominees Limited NZCSD 1,862,793 0.91%

    Profile

    since

    Note